Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, et al. Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b Headache 2021 Aug 10. doi: 10.1111/head.14196.
PMID: 34374086